The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma

OBJECTIVE: Although R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is a standard therapy for diffuse large B-cell lymphoma (DLBCL), the optimal dose for elderly patients remains unclear. METHODS AND PATIENTS: We retrospectively verified our R-CHOP dose-attenuation sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimura, Akira, Hirai, Risen, Nakamura, Miki, Takeshita, Masataka, Hagiwara, Shotaro, Miwa, Akiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355403/
https://www.ncbi.nlm.nih.gov/pubmed/30101910
http://dx.doi.org/10.2169/internalmedicine.0990-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355403/
https://www.ncbi.nlm.nih.gov/pubmed/30101910
http://dx.doi.org/10.2169/internalmedicine.0990-18

Ejemplares similares